Company / Return on Equity (ROE)
Dexcom Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
30.5%
FY2025
5-year range
10.6% / 35.4%
FY2021-FY2025
Trend
+11.2%
vs FY2024
Sector context
#9 of 148
Health Care
What the data says
Among 148 Health Care companies, Dexcom is in the top 6% for return on equity (roe). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -26.0% in FY2017 to 35.4% in FY2022.
Based on SEC 10-K filings.
30.5% in FY2025 with a 5-year CAGR of -5.0%. Top quartile in the Health Care sector.
Improved from 26.2% to 30.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -5.0pp
- 5-Year Change
- -5.0pp
- 10-Year Change
- -
Sector benchmark
Top 6% in Health CareTop 6% of 148This company 30.5% Sector average -3.2%
▼
+1040.2% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 11.2% year-over-year.
- Currently 33.7pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 26.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 30.5% | +11.2% |
| FY2024 | 27.4% | +4.7% |
| FY2023 | 26.2% | -26.1% |
| FY2022 | 35.4% | +233.5% |
| FY2021 | 10.6% | -70.0% |
| FY2020 | 35.4% | +209.3% |
| FY2019 | 11.5% | +159.8% |
| FY2018 | -19.2% | +26.4% |
| FY2017 | -26.0% | -63.0% |
| FY2016 | -16.0% | +54.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026